Get the Stockscreener App
2.3196
0.42%
0.0096
Protara Therapeutics Inc stock is traded at $2.3196, with a volume of 20,715.
It is up +0.42% in the last 24 hours and up +15.40% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$2.31
Open:
$2.34
24h Volume:
20,715
Relative Volume:
0.13
Market Cap:
$47.65M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-0.3905
EPS:
-5.94
Net Cash Flow:
$-35.26M
1W Performance:
-10.09%
1M Performance:
+15.40%
6M Performance:
-20.83%
1Y Performance:
+103.47%
1-Day Range:
$2.28
$2.39
1-Week Range:
$2.21
$2.60
52-Week Range:
$1.04
$5.24
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TARA | 2.315 | 47.65M | 0 | -42.05M | -35.26M | -5.94 |
| VRTX | 448.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.05 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.07 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
Protara Therapeutics Inc Stock (TARA) Latest News
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
HC Wainwright Analysts Decrease Earnings Estimates for TARA - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 18.1% in October - MarketBeat
Protara Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Protara to Present Key TARA-002 Phase 2 Trial Data for Bladder Cancer Treatment | TARA Stock News - StockTitan
Woodline Partners LP Acquires Shares in Protara Therapeutics Inc - GuruFocus.com
HC Wainwright Reiterates "Buy" Rating for Protara Therapeutics (NASDAQ:TARA) - MarketBeat
Protara Therapeutics Reports Increased R&D Expenses - TipRanks
Protara Therapeutics: Q3 Earnings Snapshot - CT Insider
Protara Therapeutics reports Q3 EPS (50c), consensus (52c) - TipRanks
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Protara Therapeutics: FDA Fast Track Win, Strong Trial Progress Despite Wider Q3 Loss | TARA Stock News - StockTitan
Protara Therapeutics Inc (TARA) Quarterly 10-Q Report - Quartzy
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewswire
FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia
FDA fast tracks Protara's choline chloride therapy - Investing.com
Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance
Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India
Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada
Protara reveals high choline deficiency in PS patients - Investing.com India
Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire
Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily
Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex
A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News
Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart
Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily
Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com
TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World
Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World
Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):